Current Hematologic Malignancy Reports

, Volume 8, Issue 4, pp 277–283

Multiple Myeloma: Defining the High-Risk Patient and Determining the Optimal Treatment Strategy

Multiple Myeloma (R Niesvizky, Section Editor)

DOI: 10.1007/s11899-013-0183-0

Cite this article as:
Schecter, J. & Lentzsch, S. Curr Hematol Malig Rep (2013) 8: 277. doi:10.1007/s11899-013-0183-0


Multiple Myeloma (MM) is the second most common hematologic malignancy, with approximately 21,000 new diagnoses each year. The prognosis for MM is variable and depends on several factors. This chapter highlights the clinical and pathological features of multiple myeloma to help define the “high-risk” patient. The authors also review clinical trial data in an effort to delineate the optimal treatment strategy for this group of patients. While more research in this field is needed, the available evidence supports the use of bortezomib as induction therapy and maintenance for high-risk patients with multiple myeloma.


Bortezomib Lenalidomide High-risk multiple myeloma Maintenance therapy Hematologic malignancy 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Columbia University Division of Hematology/OncologyNew YorkUSA
  2. 2.Columbia University College of Physicians and SurgeonsNew YorkUSA

Personalised recommendations